Raptor Pharmaceutical Corp. (NASDAQ:RPTP) shares rose 3.9% during trading on Tuesday . The company traded as high as $7.00 and last traded at $6.74, with a volume of 632,392 shares trading hands. The stock had previously closed at $6.49.

RPTP has been the topic of a number of research analyst reports. Wedbush reiterated a “neutral” rating and set a $4.00 price objective on shares of Raptor Pharmaceutical Corp. in a research note on Friday, May 6th. Zacks Investment Research upgraded shares of Raptor Pharmaceutical Corp. from a “hold” rating to a “buy” rating and set a $7.50 price objective on the stock in a research note on Thursday. Citigroup Inc. lowered shares of Raptor Pharmaceutical Corp. from a “buy” rating to a “neutral” rating and raised their price objective for the company from $6.00 to $8.00 in a research note on Monday. Cowen and Company reiterated a “buy” rating and set a $8.00 price objective on shares of Raptor Pharmaceutical Corp. in a research note on Sunday, April 17th. Finally, FBR & Co reiterated a “hold” rating on shares of Raptor Pharmaceutical Corp. in a research note on Sunday, June 12th. Five analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average price target of $7.21.

The stock’s market cap is $560.46 million. The firm has a 50-day moving average of $5.88 and a 200-day moving average of $4.94.

Raptor Pharmaceutical Corp. (NASDAQ:RPTP) last released its quarterly earnings results on Thursday, August 4th. The company reported ($0.16) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.18) by $0.02. During the same quarter last year, the firm earned ($0.17) earnings per share. The firm earned $32.05 million during the quarter, compared to analyst estimates of $28.52 million. Raptor Pharmaceutical Corp.’s quarterly revenue was up 37.4% on a year-over-year basis. On average, equities analysts anticipate that Raptor Pharmaceutical Corp. will post ($0.94) earnings per share for the current year.

A hedge fund recently raised its stake in Raptor Pharmaceutical Corp. stock. Globeflex Capital L P boosted its position in shares of Raptor Pharmaceutical Corp. (NASDAQ:RPTP) by 116.8% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 209,787 shares of the company’s stock after buying an additional 113,016 shares during the period. Globeflex Capital L P owned about 0.25% of Raptor Pharmaceutical Corp. worth $1,091,000 as of its most recent SEC filing.

Raptor Pharmaceutical Corp. (Raptor) is a biopharmaceutical company. The Company is focused on developing and commercializing transformative treatments for people affected by diseases. Its product, PROCYSBI (cysteamine bitartrate) is a delayed-release capsules for the management of nephropathic cystinosis in adults and children of over six years.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.